Browse by author
Lookup NU author(s): Dr John Steer, Dr Gerard Meachery
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Aims: The benefit of first-line chemotherapy in malignant pleural mesothelioma (MPM) has been established. However, this disease invariably progresses and little is known about how this disease subsequently relapses after initial treatment. Data on second-line treatment are also scarce, especially outside the context of a clinical trial. We conducted a review to observe the presentation of MPM patients when their disease progresses after initial therapy and the use of second-line therapy and its associated outcomes. Materials and methods: Patients were retrospectively identified from the Sunderland Royal Hospital and the Northern Centre for Cancer Care, Newcastle upon Tyne, UK. Data, including demographics, clinical presentation and treatment details at first line and beyond, together with its associated benefits, were collected. Related times to treatment failure (TTF), rates of symptom improvement and survival data were also collated. Results: There were 62 evaluable patients in our series. At the time of data collection, 58 patients (94%) had relapsed. At disease progression, symptoms were usually similar to those at initial presentation, but in patients with prolonged TTF (>9 months) they were more likely to relapse with clinical lymphadenopathy in the neck and axilla compared with patients with TTF <= 9 months (52% vs 13%, respectively, P < 0.05). Second-line treatment was given in 45% of patients. Twenty-one patients (36%) received second-line chemotherapy outside the context of a clinical trial and most had retreatment with pemetrexed-based chemotherapy due to a prolonged TTF. In patients treated with second-line therapy outside the remit of a clinical trial, a disease control rate was achieved in nine patients (43%, 95% confidence interval 22-64), whereas improvement in symptoms were noted in 13 patients (62%, 95% confidence interval 41-83). The median TTF in this setting was 6.5 months. Conclusion: Patients with a prolonged TTF after first-line treatment are more likely to relapse with neck and axillary lymphadenopathy. The use of second-line chemotherapy, including rechallenge treatment, in this disease is a viable option for a selected group of MPM patients. (C) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Author(s): Steer J, Bough G, Razak ARA, Meachery GJ, Hughes A
Publication type: Article
Publication status: Published
Journal: Clinical Oncology
Year: 2010
Volume: 22
Issue: 3
Pages: 231-235
Print publication date: 24/03/2010
ISSN (print): 0936-6555
ISSN (electronic): 1433-2981
Publisher: WB Saunders Co. Ltd.
URL: http://dx.doi.org/10.1016/j.clon.2010.01.009
DOI: 10.1016/j.clon.2010.01.009
Altmetrics provided by Altmetric
